Introduction
Atrial natriuretic peptides induce a decrease in blood pressure. Most studies have reported the effects of either bolus injections of atrial natriuretic peptide,' or infusions for 30 to 60 minutes.2 3 The antihypertensive response in those studies was quite different. In addition to the different modes ofadministration ofatrial natriuretic peptide the state of the renin-angiotensin-aldosterone system might play a part. 4 We therefore studied the effects of long infusions of various doses of atrial natriuretic peptide under two conditions of sodium balance in patients with essential hypertension.
Patients and methods
Human atrial natriuretic peptide dissolved in 5 g mannitol/100 ml (L-346 670, MSDRL, Rahway, New Jersey, United States) was infused at different doses (0-125, 0-25, 0-5, and 1 0 !tg/min) in three patients with essential hypertension (two men and one woman aged 35-54 with diastolic blood pressure >100 mm Hg and normal renal function). For at least two weeks before the study the patients did not take any drugs and received a diet containing 200 mmol (mEq) sodium daily. Two days before the first infusion of atrial natriuretic peptide they were admitted to hospital, where they had absolute bed rest and received a constant daily intake of sodium and fluid until the end of the study. The infusions of atrial natriuretic peptide were then repeated after a two week run in period, during which the patients received 50 mmol sodium daily.
During the study the patients adhered to a rhythm diet consisting of equal amounts of sodium, potassium, and liquids every two hours. Blood pressure was recorded continuously at two minute intervals from 1000 to 1800 with a non-invasive automatic device (Dinamap). Urine was collected by spontaneous voiding every hour from 0800 to 1800. Baseline values were measured from 1000 to 1200, and from 1200 till 1600 atrial natriuretic peptide or placebo (solvent) was infused. Measurements were confirmed till 1800.
Results
Placebo infusions resulted in a variation of blood pressure from +4% to -7% during the periods of both high and low salt intake. During the diet of 200 mmol sodium daily an infusion of 1 0 tg atrial natriuretic peptide/min initially induced a gradual decrease in blood pressure of about 10% and an increase in heart rate ( fig 1) . After two to three hours, however, blood pressure suddenly decreased in cases 1 and 3, with a concomitant decrease in heart rate. These two patients had severe symptoms of hypotension with cold sweating and dizziness, and the infusion had to be stopped. Symptoms resolved within a few minutes, and blood pressure gradually increased again.
In contrast, no decrease in blood pressure or even a pressure response occurred during the infusion of 0 5 Rg atrial natriuretic peptide/min. 2) ; during low sodium intake the curve shifted to the left. At the low sodium intake natriuresis was again observed at all doses of atrial natriuretic peptide.
Discussion
The gradual decrease in blood pressure and increase in heart rate, initially observed during the infusion of 1-0 rg atrial natriuretic peptide/min in patients receiving a high salt intake, is characteristic of treatment with a vasodilator and is compatible with data from animal experiments.5 After two to three hours, however, the heart rate suddenly fell in parallel with a severe hypotensive collapse ( fig  1) . Such an occurrence has not, to our knowledge, been reported previously. Other workers have used bolus injections of 100 [tg atrial natriuretic peptide or infusions of 3 [tg/min for 30 to 60 minutes without observing symptomatic hypotension.23 The difference in duration of administration of atrial natriuretic peptide might be responsible for our observation; a cumulative effect of atrial natriuretic peptide is less likely as it is rapidly metabolised.3
We showed that salt depletion increases the effect of atrial natriuretic peptide on blood pressure (fig 2) . This emphasises the potential risk of infusion of atrial natriuretic peptide in essential hypertension. Even low doses that do not influence the blood pressure during high salt intake cause a hypotensive collapse during low salt intake. Because of the pronounced and reproducible symptomatic hypotension that we observed no more patients were enrolled in this study. During all infusions of atrial natriuretic peptide, even at doses that did not decrease blood pressure, sodium excretion increased, suggesting that it is not only natriuresis that is responsible for the change in blood pressure. 
Patients and methods
Six patients with progressive autonomic failure (four men and two women, aged between 55 and 68) were studied; two also had multiple system atrophy.2 All had severe sympathetic failure and symptomatic postural hypotension. Drugs (fludrocortisone acetate and ephedrine) had -been withdrawn three days previously. Their intake of fluid -and food was unrestricted, and they maintained their normal level of mobility. Urine was collected over periods of 12 hours (9 am to 9 pm and 9 pm to 9 am), and volume, osmolality, and excretion ofsodium and potassium were measured. Patients were weighed at 9 am and 9 pm. Blood pressure (mercury sphygmomanometer) and heart rate (radial pulse) were measured after the patients had been supine for at least 10 minutes and after they had been sitting on the edge of the bed for two minutes. Standing blood pressure was not recorded because some found it difficult to stand, particularly -in the morning. Measurements were taken before meals to avoid postcibal hypotension.3 On the third day haemoglobin concentration, packed cel volume, blood urea, plasma sodium and potassium concentrations, and plasma osmolality were measured. After three control days the observations were repeated, with the addition of 2 ig desmopressin given intramuscularly at 8 pm on the first night, followed by 4 ,ug for two further nights. Blood measurements were repeated after three days' treatment with desmopressin. Patients then either restarted their previous treatment or entered a pilot study to determine a beneficial therapeutic dose of intranasal desmopressin. Five patients who completed the study are analysed here as a group and one:patient is discussed separately as she developed hyponatraemia. Paired and unpaired t tests were used for statistical analysis. Results are expressed as means (SEM).
Results

CONTROL PERIOD
All patients had nocturnal polyuria, with an overnight excess of 169 (79) ml (table I) . Overnight weight loss was 0-74 (0-07) kg (p<001). Nocturnal urinary sodium concentration was greater (p<005) and urinary osmolality was lower than during the day. Supine blood pressure was lowest in the morning and rose during the day (table II) . The postural fall in blood pressure on sitting was similar in the morning and evening, but symptoms were worse in the morning, probably because supine blood pressure was lower.
DESMOPRESSIN PERIOD
After treatment with desmopressin there was a pronounced reduction in nocturnal polyuria (p<0-01) (see table I) and overnight weight loss was reduced. Body weight rose by 1-35 (006) kg (p<0-01) over three days. Supine blood pressure was higher in the morning (see table II), when the postural fall was maximally reduced (p<005). Sitting blood pressure improved during the day. Overnight urinary osmolality " higher (p<0 05)
